Anhui Beijing Brazil China Chinese Chongqing Coronavirus Covid-19 Ecuador education Hunan Indonesia Manufacturing Pakistan Peru United Arab Emirates University Uzbekistan Vaccine Xinhua
A leading Chinese vaccine maker said it has commenced phase-3 clinical trials for its Covid-19 vaccine and is planning to recruit 29,000 volunteers across the world. This is China’s first phase-3 efficacy study for a Recombinant subunit Covid-19 vaccine candidate, Anhui Zhifei Longcom Biopharmaceutical, said in a statement on Thursday. Jointly developed by the company and the Institute of Microbiology under the Chinese Academy of Sciences, the vaccine was issued a clinical research permit from the National Medical Products Administration on June 19. The company said the research, which plans to enroll up to 29,000 adults aged 18 and up,…
News Timeline:
Track the development of this news story across the Internet.